MHRA Accreditation

In January 2009 we were awarded Supplementary Accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA). This is one of the highest levels of accreditation in Europe and confirms that we are qualified to perform the full range Phase I trials, including First-in-Human (FIH) studies for low molecular weight chemical entities and biologics.

The MHRA voluntary accreditation scheme was introduced in April 2008 in line with recommendations from the MHRA clinical trial expert advisory group to maximise subject safety. The scheme provides formal guidance on the standards expected in a clinical unit conducting FIH studies.